⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AMRX News
Amneal Pharmaceuticals, Inc. Class A Common Stock
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease
businesswire.com
AMRX
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
globenewswire.com
AMRX
Zambon Biotech annuncia l'arruolamento del primo paziente nello studio clinico di Fase 3b ADIP su IPX203 nella malattia di Parkinson
businesswire.com
AMRX
Zambon Biotech annonce la première administration d'IPX203 à un patient dans le cadre de l'étude clinique ADIP de phase 3b dans la maladie de Parkinson
businesswire.com
AMRX
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease
businesswire.com
AMRX
Zambon Biotech meldet erste Dosisverabreichung der klinischen Phase-3b-Studie ADIP zu IPX203 bei Parkinson
businesswire.com
AMRX
Food Preservatives Market Growth Outlook: CAGR of 4.7% and Value Reaching USD 5.01 Billion by 2032
globenewswire.com
AMRX
Health Impact Alliance Launches Life.Studio Sweden to Advance Intelligent Care and Transform Healthy Aging
businesswire.com
AMRX
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
globenewswire.com
AMRX
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
globenewswire.com
AMRX